(sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product. Genzyme has submitted a marketing ...

On October 22, 2007, the US Food and Drug Administration (FDA) granted marketing approval to Genzyme for Renvela, a new treatment for the control of serum phosphorus in patients with chronic ...

Genzyme's filing in Europe for Renvela includes both tablet and powder formulations for the control of serum phosphorus in adult hyperphosphatemic CKD patients. The CHMP opinion will be forwarded ...

About Renvela Renvela® (sevelamer carbonate) is indicated in the United States for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Renvela is ...

Oct 22 (Reuters) - Genzyme Corp said U.S. health regulators approved its phosphate binder, Renvela, for patients with chronic kidney disease on dialysis. The biotechnology company also plans to ...

SAN FRANCISCO (MarketWatch) -- Biotech drugmaker Genzyme Corp. said Monday it received Food and Drug Administration approval for its next-generation kidney treatment Renvela. The treatment is used ...